Scalp hypothermia: a comparison of ice packs and the Kold Kap in the prevention of doxorubicin-induced alopecia.

1983 ◽  
Vol 1 (1) ◽  
pp. 33-37 ◽  
Author(s):  
J C Dean ◽  
K S Griffith ◽  
T C Cetas ◽  
C L Mackel ◽  
S E Jones ◽  
...  
Keyword(s):  
Hair Loss ◽  
Side Effect ◽  
Endothermic Reaction ◽  
Plastic Bags ◽  
Scalp Hypothermia ◽  
Crushed Ice ◽  
Ice Pack

Two methods of scalp hypothermia were compared in preventing alopecia, a side effect of doxorubicin chemotherapy that has a significant psychologic impact on the patient. Thirty-three patients received scalp ice packs consisting of crushed ice in plastic bags. Twenty-nine patients received Kold Kap, a device that produces chilling via an endothermic reaction. Scalp hypothermia was applied for 5-10 min before the doxorubicin bolus and left in place for 30-40 min afterward. The percent of hair loss was rated at each visit and photographs were used to further quantitate any hair loss. Sixty-three percent of Kold Kap and 56% of ice pack patients had good or better protection and did not require wigs. Excellent protection (less than 25% loss) was provided for 51% of Kold Kap and 33% of ice pack patients. Similar protection was provided to Kold Kap patients regardless of dose, while ice pack patients received significantly better protection if their doxorubicin doses were less than 50 mg. Scalp hypothermia is an effective method of preventing doxorubicin-induced alopecia.

Skin and mucosal alterations

2007 ◽  
pp. 635-652
Keyword(s):  
Body Image ◽  
Cancer Treatment ◽  
Advanced Cancer ◽  
Oral Mucositis ◽  
Hair Loss ◽  
Side Effect ◽  
Oral Care ◽  
Scalp Cooling ◽  
It Impacts ◽  
Scalp Hypothermia

Hair loss (alopecia) 636 Scalp cooling (scalp hypothermia) 638 Oral mucositis and related problems 640 Oral mucositis: managing the process and symptoms 644 Oesophagitis 646 Oral care in advanced cancer 647 Malignant wounds 648 Lymphoedema 650 Hair loss can be a distressing side effect of cancer treatment; it impacts on body image and feelings of attractiveness, creates anxiety and causes a visual reminder of the disease and treatment. Alopecia is not a major side effect for most people, but a small group of patients will become extremely distressed by it....

scholarly journals Trastuzumab Induced Chemobrain, Atorvastatin Rescued Chemobrain with Enhanced Anticancer Effect and without Hair Loss-Side Effect

2019 ◽  
Vol 8 (2) ◽  
pp. 234 ◽  
Author(s):  
Seonhwa Lee ◽  
Hae-June Lee ◽  
Hyunji Kang ◽  
Eun-Ho Kim ◽  
Young-Cheol Lim ◽  
...  
Keyword(s):  
Glucose Metabolism ◽  
Gray Matter ◽  
Hair Loss ◽  
Side Effect ◽  
Therapeutic Efficacy ◽  
Statistical Parametric Mapping ◽  
Growth Factor Receptor ◽  
Morphometry Analysis ◽  
Chemo Brain ◽  
Matter Concentration

The authors identified that chemo-brain was induced after trastuzumab (TZB) therapy. In addition, atorvastatin (ATV) could rescue chemo-brain during trastuzumab (TZB) therapy. Enhanced therapeutic effect of TZB was confirmed after ATV therapy. We also investigated that there was no hair loss side effect due to ATV therapy. In an animal model, 150 μg TZB and five serial doses of 20 mg/kg ATV were administered. 18F-fluorodeoxyglucose Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) data were acquired. Statistical parametric mapping analysis and voxel-based morphometry analysis were performed to identify differences in glucose metabolism and gray matter concentration. The enhanced therapeutic efficacy of TZB after ATV treatment was assessed using a human epidermal growth factor receptor 2-positive gastric cancer model. We found a decrease in cerebral glucose metabolism and gray matter concentration in the frontal lobe following TZB therapy (p < 0.005). After subsequent ATV administration, glucose metabolism and regional gray matter concentration were rescued (p < 0.005). Cognitive impairment due to TZB and the rescue effect of ATV were confirmed using a passive avoidance test and quantitative real-time reverse transcription PCR. Furthermore, the penetration and accumulation of TZB in tumors increased by 100% after ATV co-administration, which resulted in an enhanced anti-cancer effect. Our study collectively demonstrates that ATV co-administration with TZB rescued the TZB-induced chemo-brain and enhances the therapeutic efficacy of TZB in tumors. We also showed that there was no hair loss during ATV therapy.

Hair restoration

2021 ◽  
pp. 1373-1378
Author(s):  
Nagham Darhouse
Keyword(s):  
Medical Treatment ◽  
Hair Loss ◽  
Side Effect ◽  
Medical Condition ◽  
Correct Diagnosis ◽  
Hair Follicles ◽  
Men And Women ◽  
Detailed History ◽  
Dermatological Condition ◽  
Treatment Surgery

Hair restoration focuses on replacing hair where it has been lost, although there is also a demand for hair to be placed where it is desired, but lacking, for a perceived aesthetic gain. For both men and women, hair loss can be devastating and lead to loss of confidence and self-esteem. Hair restoration can be beneficial but treatment should be tailored to the individual’s needs and the correct diagnosis for the hair loss needs to be determined through a detailed history, thorough examination, and appropriate investigations. The average human has over 5 million hair follicles of which only about 100,000 are located on the scalp. While it is loss of scalp hair that is often most noticeable and distressing, eyebrow and eyelash hair loss is also very obvious in both sexes, as is loss of beard and moustache hair in men. Hair loss may be localized or generalized, part of a medical condition, a side effect of medications, the result of a dermatological condition, or genetically predetermined. Hair restoration can be achieved through medical treatment, surgery, and non-surgical alternatives.

Effectiveness of scalp cooling in reducing chemotherapy-induced alopecia: A single center prospective study in Lebanon.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e12075-e12075
Author(s):  
Nour Haidar ◽  
Lewis Nasr ◽  
Fadi Nasr
Keyword(s):  
Breast Cancer ◽  
Prospective Study ◽  
Hair Loss ◽  
Side Effect ◽  
Chemotherapy Regimen ◽  
Stage I ◽  
P Value ◽  
Scalp Cooling ◽  
Multiple Cycles ◽  
The One

e12075 Background: Hair loss (alopecia) is recognized as one of the most common and distressing side effects of chemotherapy. The scalp cooler first used in 1970s against the Chemotherapy CIA (chemotherapy induced alopecia). This study aimed at assessing the effectiveness of scalp cooling (PAXMAN Cooler ORBIS II SCALP COOLER) in reducing chemotherapy-induced alopecia. Methods: This prospective study was conducted at the Mount-Lebanon Hospital in the one day chemotherapy between 01 January 2017 and 31 December 2018. 109 women diagnosed with breast cancer with stage I or II undergoing neoadjuvant, and adjuvant chemotherapy were enrolled. Patients with scalp cooling 54.1% (n=59), control 45.9 % (n=50). Scalp cooling done by using the scalp cooling device. The primary end point was to assess the hair loss using the dean’s scale after multiple cycles of chemotherapy. The clinical assessment and alopecia evaluation were done after each chemotherapy cycle. The secondary endpoint was the side effect of the scalp cooler such as headache. Results: The Mean age was 55.73 ± 11.9 years. 82.56 %received Anthracycline-based chemotherapy regimen with Docetaxel, and 14.69 % Anthracycline-based chemotherapy regimen with Paclitaxel and 2.75 % took only anthracycline with cyclophosphamide. The effectiveness of hair preservation was successfully reported as 62.7% grade 0, 22.01 % grade 1 and 15.29% grade 2. There were highly significant differences between patients underwent scalp cooling and patients without scalp cooling with different regimens of chemotherapy (P value <0.0001). The major side effect, the headache where was reported in 25.7% from the total (P value <0.0001). Conclusions: Hair preservation in stage I , II breast cancer undergoing multiple regimens of chemotherapy was significantly more effective in the scalp cooling group.

Hair Loss in the Course of Lithium Treatment: A Report of Two Cases*

1983 ◽  
Vol 28 (2) ◽  
pp. 132-133 ◽  
Author(s):  
Ramzy Yassa ◽  
Jambur Ananth
Keyword(s):  
Thyroid Function ◽  
Hair Loss ◽  
Side Effect ◽  
Lithium Treatment ◽  
Lithium Therapy ◽  
The Other ◽  
Thyroid Function Tests ◽  
Underlying Factor ◽  
Function Tests ◽  
Benign Thyroid

Two cases of hair loss attributed to lithium therapy are presented. In one case, lithium did not have to be discontinued, and in the other, hair loss led to noncompliance. This side effect is usually benign. Thyroid function tests should always be performed to exclude hypothyroidism as the underlying factor for this symptom.

Scalp hypothermia in the prevention of doxorubicin-induced hair loss

1988 ◽  
Vol 11 (3) ◽  
pp. 170???173 ◽  
Author(s):  
Giaccone Giuseppe ◽  
Francesco Di Giulio ◽  
Maria Pia Morandini ◽  
Calciati Alessandro
Keyword(s):  
Hair Loss ◽  
Scalp Hypothermia

scholarly journals Headgear-induced temporary pressure alopecia

2019 ◽  
Vol 46 (4) ◽  
pp. 335-342
Author(s):  
Catherine Liu ◽  
Faisal Abbas ◽  
Jadbinder Seehra
Keyword(s):  
Hair Loss ◽  
Side Effect ◽  
Predisposing Factors ◽  
Tissue Hypoxia ◽  
Mechanical Trauma ◽  
Excessive Pressure ◽  
Hair Regrowth ◽  
Psychosocial Wellbeing ◽  
Rare Phenomenon ◽  
Rare Side Effect

The development of hair loss associated with headgear use is a rare phenomenon. Pressure alopecia is a condition characterised by localised, non-scarring hair loss attributed to a mechanical cause. Factors such as prolonged periods of peri- and postoperative immobility have been implicated, as well as immunological and genetic predisposing factors. If the mechanical trauma is very prolonged, there is a risk of permanent follicle damage due to tissue hypoxia. A 13-year-old boy wore high-pull headgear as part of his orthodontic management. Within four weeks of headgear wear, localised areas of hair loss were seen corresponding with the areas of contact with the force delivery modules of the headgear. The patient experienced bullying at school as a result of this hair loss. Hair regrowth resumed after headgear use was discontinued, therefore confirming the diagnosis of temporary pressure alopecia. Temporary pressure alopecia is a rare side effect of orthodontic headgear. Alopecia can negatively impact an individual’s psychosocial wellbeing; therefore, caution should be taken to avoid prolonged or excessive pressure in susceptible individuals and headgear patients should be regularly monitored.

Hair Loss as a Side Effect of Lamotrigine Treatment

2006 ◽  
Vol 163 (8) ◽  
pp. 1451-1451 ◽  
Author(s):  
THOMAS HILLEMACHER ◽  
STEFAN BLEICH ◽  
JOHANNES KORNHUBER ◽  
HELGE FRIELING
Keyword(s):  
Hair Loss ◽  
Side Effect
Sign in / Sign up

Export Citation Format

Share Document